Original Publication Date: 1 February, 2014
Publication / Source: Future Oncology
Authors: Geert A Cirkel, Christa G Gadellaa-van Hooijdonk, Marco J Koudijs et al.
Tumor heterogeneity is regarded as a major obstacle to successful personalized cancer medicine. The lack of reliable response assays reflective of in vivo tumor heterogeneity and associated resistance mechanisms hampers identification of reliable biomarkers. By contrast, oncogene addiction and paracrine signaling enable systemic responses despite tumor heterogeneity. This strengthens researchers in their efforts towards personalized cancer medicine.